Yanagi Daisuke, de Vries Garry Cores, Rahardjo Dadik, Alimsardjono Lindawati, Wasito Eddy Bagus, De Ismoedijanto, Kinoshita Shouhiro, Hayashi Yoshitake, Hotta Hak, Osawa Ro, Kawabata Masato, Shirakawa Toshiro
Infectious Disease Center, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Diagn Microbiol Infect Dis. 2009 Aug;64(4):422-6. doi: 10.1016/j.diagmicrobio.2009.04.006.
Typhoid fever remains a major health problem in developing countries. Fluoroquinolones such as ciprofloxacin emerged as the 1st-choice treatment of enteric fever, including typhoid, in the 1990s. Recently, Salmonella typhi strains with resistance to ciprofloxacin have been increasingly reported in several countries, although the fluoroquinolone-resistant clinical strain has not been reported in Indonesia. In the present study, we examined the drug susceptibility and the presence of gyrA mutations in 17 clinical strains of S. typhi isolated from Surabaya, Indonesia, in 2006 (9 strains) and 2008 (8 strains). Although all 9 isolates from 2006 were sensitive to all tested antibiotics and had no mutation in the gyrA gene, all 8 isolates from 2008 were resistant to nalidixic acid and ampicillin and had a gyrA mutation at codon 87. In addition, 3 of 8 strains from 2008 showed multiple drug resistance, including resistance to chloramphenicol, trimethoprim-sulfamethoxazole, and ciprofloxacin. Therefore, newer drugs, such as ceftriaxone, cefixime, and azithromycin, might be effective in this situation. This is the 1st report of the emergence of fluoroquinolone-resistant clinical strains of S. typhi with a gyrA mutation, and it reveals a health risk due to multidrug-resistant strains in Indonesia.
伤寒热在发展中国家仍然是一个主要的健康问题。20世纪90年代,环丙沙星等氟喹诺酮类药物成为治疗伤寒等肠热病的首选药物。最近,几个国家越来越多地报告了对环丙沙星耐药的伤寒杆菌菌株,不过印度尼西亚尚未报告对氟喹诺酮耐药的临床菌株。在本研究中,我们检测了2006年(9株)和2008年(8株)从印度尼西亚泗水分离出的17株伤寒杆菌临床菌株的药敏性以及gyrA基因突变情况。尽管2006年的所有9株分离菌对所有测试抗生素均敏感且gyrA基因无突变,但2008年的所有8株分离菌对萘啶酸和氨苄西林耐药,且在第87位密码子处有gyrA基因突变。此外,2008年的8株菌株中有3株表现出多重耐药,包括对氯霉素、甲氧苄啶 - 磺胺甲恶唑和环丙沙星耐药。因此,在这种情况下,头孢曲松、头孢克肟和阿奇霉素等新型药物可能有效。这是首次报告出现带有gyrA基因突变的对氟喹诺酮耐药的伤寒杆菌临床菌株,并且揭示了印度尼西亚多重耐药菌株带来的健康风险。